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ABSTRACT: Background. The purpose of this study was to describe the
relationship of p16 and epidermal growth factor receptor (EGFR)
expression with survival in surgically treated patients who had
oropharyngeal or oral cavity squamous cell carcinoma (SCC).
Methods. Tissue from 36 patients with oropharyngeal SCC and 49
patients with oral cavity SCC treated between 1997 and 2001 was
imbedded and immunostained using a tissue microarray.
Results. The p16 was positive in 57% and 13% of patients with
oropharyngeal SCC and oral cavity SCC, respectively. EGFR was positive
in 60% and 63% of patients with oropharyngeal SCC and oral cavity SCC,
respectively. In patients with oropharyngeal SCC, p16 expression was
associated with improved disease-specific survival (DSS), overall survival
(OS), and time to recurrence (TTR) (p < .01, < .01, and <.01,
respectively). EGFR expression was associated with poorer DSS, OS, and
TTR (p < .01, ¼ .01, and < .01, respectively). For oropharyngeal SCC,
when examining both p16 and EGFR expression as combined biomarkers,
high p16 expression coupled with low EGFR expression was associated
with improved DSS (p p16¼ .01; p EGFR¼ .01). Patients with oral cavity
SCC showed no association between biomarker and outcome.
Conclusions. For patients with oropharyngeal SCC, high p16 and low
EGFR were associated with improved outcome, suggesting a predictive
role in surgically treated patients. VC 2012 Wiley Periodicals, Inc. Head
Neck 35: 1083–1090, 2013
KEY WORDS: oropharyngeal neoplasm, oral cavity neoplasm,
p16(INK4A), EGFR protein, human papillomavirus
INTRODUCTION
Optimal treatment of oropharyngeal and oral cavity
squamous cell carcinoma (SCC) should be guided by both
patient characteristics and tumor biology. Conventional
treatment of locally advanced oropharyngeal and oral cav-
ity SCC involves multimodality therapy, which includes a
combination of surgery, radiotherapy, and cisplatin-based
chemotherapy. Primarily, clinical factors guide decisions
on the type of treatment prescribed to the patient. More
recently, however, prognostic biological markers, in addi-
tion to clinical parameters, have improved the ability to
predict outcome, particularly in patients with oropharyn-
geal SCC. Among them, expression of p16 and epidermal
growth factor receptor (EGFR), assessed through immu-
nohistochemistry, have been shown to help further char-
acterize the behavior of tumors and ultimately may aid in
the design of clinical trials that will select patients requir-
ing treatment escalation or de-escalation.
P16 is an excellent surrogate marker for high-risk
human papillomavirus (HPV) in patients with oropharyn-
geal SCC, reflecting the inactivation of the retinoblastoma
tumor suppressor protein by the oncoprotein E7.1 Many
studies have demonstrated the correlation between p16
expression and improved survival, particularly in patients
with oropharyngeal SCC and particularly in those treated
with nonsurgical therapies.1–3 EGFR plays an important
role in the regulation of cellular proliferation and survival
in epithelial tumors. Alterations in EGFR signaling path-
ways lead to decreased apoptosis of tumor cells, enhanced
invasiveness, cell migration, angiogenesis, and metasta-
sis.4 Many studies have demonstrated an association
between elevated expression of EGFR and poorer sur-
vival, although the majority of these studies focus on non-
surgical treatment of patients with oropharyngeal
SCC.2,3,5,6
At the University of Michigan, standard treatment for
patients with locally advanced oropharyngeal SCC
includes a combination of chemotherapy and radiother-
apy. A recent trial (UMCC-9921) demonstrated the
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efficacy of both p16 and EGFR in predicting survival in
patients with oropharyngeal SCC treated with nonsurgical
modalities.2 Patients with increased expression of p16
had improved survival, whereas those with elevated
expression of EGFR had poorer survival. Less is known
about the ability of these biomarkers to predict outcome
in patients with oropharyngeal SCC who are treated sur-
gically. Furthermore, the ability of these biomarkers to
predict survival in patients with oral cavity SCC has yet
to be investigated. The purpose of this study was to eval-
uate and contrast biomarker expression in surgically
treated patients with oropharyngeal and oral cavity SCC.
MATERIALS AND METHODS
Study design
This was a prospective cohort study.
Study population
Eligibility criteria for this study included patients with
previously untreated oropharyngeal or oral cavity SCC
who were treated with primary surgical extirpation.
Patients were excluded if they presented with a synchro-
nous primary neoplasm of the head and neck, a history of
previous head and neck cancer, a history of previous sur-
gery or radiation therapy to the upper aerodigestive tract,
or distant metastatic disease. Eighty-five patients were
enrolled from 1997 to 2001 and followed prospectively
for outcome (disease status and survival). These 85
patients were separated into 2 cohorts: 36 patients with
oropharyngeal SCC and 49 with oral cavity SCC. These
cohorts were each analyzed separately. The cohort sizes
were small because of the stringent inclusion criteria. The
inclusion criteria of no prior treatment limited the cohort
size the most. Table 1 demonstrates baseline demo-
graphics, staging, and treatment modality of the patient
cohorts with oropharyngeal and oral cavity SCC. Patients
continue to undergo regular follow-up and have currently
been followed for 9 years. With respect to the 36 patients
who made up the oropharyngeal SCC cohort, the 5-year
disease-specific survival (DSS) and overall survival (OS)
were 59% and 38%, respectively. At 5 years of follow-
up, 42% of patients (15 of 36) were alive and free of dis-
ease, 3% (1 of 36) were alive with disease, 36% (13 of
36) were dead of disease, 6% (2 of 36) were dead of sec-
ond primary neoplasm, and 14% (5 of 36) were dead of
intercurrent illness.
The 5-year DSS and OS estimates for the 49 patients
with oral cavity SCC were 60% and 54%, respectively.
At 5 years of follow-up, 59% of patients (29 of 49) were
alive and free of disease, 29% (14 of 49) were dead of
disease, 2% (1 of 49) were dead of a second primary tu-
mor, 8% (4 of 49) were dead of intercurrent illness, and
2% (1 of 49) were lost to follow-up.
Variables under study
Patients were evaluated at baseline for clinical covari-
ates (age, sex, tobacco exposure, alcohol history, tumor
site, and stage). Tobacco history and alcohol status were
classified as "never,’’ "past’’ (quit 6 months ago), or
"current.’’ Staging was based on the 2002 American Joint
Committee on Cancer staging system. Pretreatment biop-
sies of the primary tumor were used to construct a tissue
microarray to evaluate the expression of biomarkers (p16
and EGFR). After surgical extirpation, pathology speci-
mens were evaluated for perineural/perivascular invasion,
histologic grade, and nodal characteristics.
Immunostaining and scoring
Tumor specimens used to construct the tissue microar-
ray were deparaffinized, rehydrated, and peroxidase-
quenched (Dako Cytomation, Glostrup, Denmark). For
antigen retrieval, slides were incubated with citrate buffer
(p16; 30 minutes at 92C) or with pepsin (EGFR; 10
minutes at 37C) and were blocked with horse serum (30
minutes at 25C). Primary antibody, p16/16P04, (Lab-
Vision, Fremont CA) and EGFR/31G7 (Zymed Laborato-
ries, South San Francisco, CA), were added for 1 hour
and were probed with avidin/biotin peroxidase (ABC Kit;
Vector Laboratories, Burlingame, CA).2
Antibody binding was scored by a pathologist (K.G.C.)
who was blinded to the clinical outcome. Based on previ-
ous experience from our institution,2,7 p16 expression
was scored based on the proportion of tumor staining
TABLE 1. Patient and tumor characteristics.
Oral cavity
SCC n ¼ 49
Oropharyngeal
SCC n ¼ 36
Age: mean (SD) 57.2 (17.0) 52.3 (11.0)
Sex
Male 17 (35%) 5 (14%)
Female 32 (65%) 31 (86%)
Smoking history
Never 3 (6%) 2 (6%)
Past 36 (73%) 29 (81%)
Current 6 (12%) 4 (11%)
Unknown 4 (8%) 1 (3%)
Adjuvant treatment
None 15 (30%) –
Radiotherapy 33 (66%) 31 (86%)
Chemoradiotherapy 2 (4%) 5 (14%)
T classification (clinical)
T1 5 (10%) 1 (3%)
T2 15 (31%) 9 (25%)
T3 10 (20%) 12 (33%)
T4 19 (39%) 14 (39%)
N classification (pathologic)
N0 22 (45%) 5 (14%)
N1 8 (16%) 4 (11%)
N2 19 (39%) 24 (69%)
N3 – 2 (6%)
AJCC stage
I 4 (8%) –
II 8 (16%) –
III 9 (18%) 6 (17%)
IV 26 (57%) 30 (83%)
Histologic grade
Well 9 (20%) 2 (6%)
Moderate 30 (65%) 19 (54%)
Poor 7 (15%) 14 (40%)
Perineural invasion 10 (20%) 4 (11%)
Perivascular invasion 7 (14%) 8 (22%)
Nodal ECS 12 (24%) 21 (58%)
Abbreviations: SCC, squamous cell carcinoma; AJCC, American Joint Committee on Cancer;
ECS, extracapsular spread.
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positive using an ordinal scale from 1 to 4: 1 was less
than 5%, 2 was 5% to 20%, 3 was 21% to 50%, and 4
was 51% to 100%. Patients with a score greater than 1
were considered positive for p16. EGFR expression was
scored based on the level of intensity using a scale from
1 to 4; 1 equal to no staining, 2 equal to low intensity, 3
equal to moderate, and 4 equal to high intensity. Patients
with a score greater than 2 were considered positive for
EGFR. Scores for 3 cores of tumor from each patient
were averaged. Of the 36 patients with oropharyngeal
SCC eligible for the study, 35 had sufficient specimens
for immunostaining. Of the 49 patients with oral cavity
SCC eligible for the study, 46 had sufficient specimens
for immunostaining.
Response variables
Patients were evaluated for the following outcomes:
DSS defined by the time from primary surgery to death
from oral cavity SCC or oropharyngeal SCC, OS defined
by the time from primary surgery to all-cause mortality,
and time to recurrence (TTR) defined by the time from
primary surgery to the first recurrence.
Statistical analysis
Baseline patient and tumor characteristics were tabu-
lated. Patient-level averages for proportion of p16 expres-
sion and intensity of EGFR expression were used in the
analysis. For the assessment of bivariate associations
between markers and covariates, rank-based statistical
methods were used. The Kaplan–Meier method and the
log-rank test were used to compare the homogeneity of
survival rates within and between categories of discrete
variables. Only patients who had sufficient specimen for
immunostaining were considered for the association
between markers and survival. The Cox proportional haz-
ards models were used to assess the markers’ effects
beyond the effects of the clinical covariates. Likelihood
ratio statistics were used to determine statistically signifi-
cant differences between the models. All statistical analy-
ses were done with SAS version 9.0 (SAS Institute,
Carey, NC). A 2-tailed p value of .05 or less was consid-
ered statistically significant.
The Institutional Review Board at the University of
Michigan granted approval for this study.
RESULTS
Prevalence of p16 and epidermal growth factor receptor
The prevalence of p16 positivity in patients with oro-
pharyngeal and oral cavity SCC were 57% (20 of 35) and
13% (6 of 46), respectively. The mean proportion of cells
staining positive for p16 was higher in the oropharynx
(Figure 1A; p < .01). Of the 20 patients who were posi-
tive for p16 in the oropharynx, 95% (19 of 20) had a p16
score of 4. In contrast, of the 6 patients who were posi-
tive for p16 in the oral cavity, only 50% (3 of 6) had a
score of 4.
The prevalence of EGFR positivity in the oropharynx
and oral cavity were 60% (21 of 35) and 63% (29 of 46),
respectively. In addition, there was no statistically signifi-
cant difference in mean intensity of EGFR staining
between oropharyngeal and oral cavity tumors (Figure
1B; p ¼ .57).
FIGURE 1. Comparison of mean score of immunostain across subsites. (A) Box plot shows a significantly lower mean score of p16 proportion in
oral cavity squamous cell carcinoma (SCC) versus oropharyngeal SCC. (B) A similar mean score of epidermal growth factor receptor (EGFR)
intensity is seen between oral cavity SCC and oropharyngeal SCC. Dot, mean; box, 25th to 75th percentile; horizontal bar, median. [Color figure can
be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Biomarker and survival analysis
p16 survival analysis. For oropharyngeal SCC, patients with
a higher p16 expression experienced significantly
improved DSS (p < .01) and OS (p < .01) compared
with those with a low p16 expression at 9 years of fol-
low-up (Figure 2). In addition, patients with a higher
p16 expression had a significantly longer TTR (p <
.01). At 5 years, those with the highest p16 staining
proportion (51% to 100%; score ¼ 4) had a DSS of
75% versus those with a staining proportion of less than
5% (score ¼ 1) who had a DSS of 23%. Similarly,
those with the highest p16 staining proportion (51% to
100%; score ¼ 4) had an OS of 57% versus those with
a staining proportion of less than 5% (score ¼ 1) who
had an OS of 20%.
Forty-three percent of the patients (15 of 35) with oro-
pharyngeal SCC were negative for p16 expression, and
this finding was associated with a poorer DSS and OS.
Of these 15 patients, 9 were dead from disease at 5 years
of follow-up. The pattern of recurrence included 1 of 9
local, 1 of 9 regional, 4 of 9 distant, 2 of 9 local/regional,
and 1 of 9 local/regional/distant. In summary, distant dis-
ease was seen in 5 of 9 patients with oropharyngeal SCC
who were negative for p16 expression.
Of the patients with oropharyngeal SCC, 57% (20 of
35) were positive for p16 expression, and this was associ-
ated with improved survival. Of these 20 patients, 4 were
dead from disease at 5 years of follow-up. Interestingly,
in this group of patients who were p16-positive, all 4
died of distant disease.
In oral cavity SCC, due to the low prevalence of p16
(13%), the ability to stratify patients by this biomarker
was not feasible when performing survival analysis.
Epidermal growth factor receptor survival analysis
For oropharyngeal SCC, patients with none or low
EGFR expression (score ¼ 1 or 2) experienced signifi-
cantly improved DSS (p < .01) and OS (p ¼ .01) com-
pared with those with a moderate or high level of expres-
sion (score ¼ 3 or 4) at 9 years of follow-up (Figure 3).
In addition, patients with a lower EGFR expression had a
significantly increased TTR (p < .01). At 5 years, those
with none or low expression had a DSS of 95% versus
those with a moderate or high expression, who had a
DSS of 38%. Similarly, those with none or low expres-
sion had an OS of 68% versus those with a moderate or
high expression, who had an OS of 25%.
Sixty percent (21 of 35) of the patients with oropharyn-
geal SCC were positive for EGFR expression, and this
was associated with poorer DSS and OS. Of these 21
patients, 12 were dead from disease at 5 years of follow-
up. Most patients died of distant disease. The pattern of
recurrence was 9 of 12 distant, 2 of 12 local/regional,
and 1 of 12 local recurrence.
Forty percent (14 of 35) of the patients with oropharyn-
geal SCC were negative for EGFR expression, and this
was associated with improved DSS and OS. Of these 14
patients, only 1 died of disease at 5 years of follow-up,
and this was from a regional recurrence.
Combined marker survival analysis
For oropharyngeal SCC, when examining both p16 and
EGFR expression as combined markers in a multivariable
model, high p16 expression coupled with low EGFR
expression was associated with improved DSS (p p16 ¼
.01; p EGFR ¼ .01; Figure 4). At 5 years, the DSS for
FIGURE 2. Survival of patients with oropharyngeal squamous cell carcinoma (SCC) according to p16 proportion. (A) Those with a high p16
expression have significantly improved disease-specific survival (DSS). (B) Those with a high p16 expression have improved overall survival (OS).
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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the 10 patients with high p16 proportion and low EGFR
intensity was 100%. In contrast, the DSS for the 12
patients with low p16 proportion and high EGFR intensity
was 17%.
Clinical covariates and outcome
In patients with oropharyngeal SCC, 58% (21 of 36)
had evidence of extracapsular spread in the lymph nodes
and 22% (8 of 36) had evidence of perivascular invasion
in the primary tumor. In univariate analysis, extracapsular
spread and perivascular invasion were each associated
with poorer DSS (p ¼ .026 and .014, respectively). How-
ever, multivariable regression changed these findings.
When a multivariable regression was performed on
extracapsular spread (ECS), perivascular invasion, and
EGFR, only EGFR remained a significant predictor of
DSS (p ¼ .002). For patients with oropharyngeal SCC,
higher levels of EGFR expression were associated with a
positive smoking history, either past or current (r ¼
0.385; p ¼ .025; Figure 5). This finding must be tem-
pered by the fact that of the 35 patients, the majority (29
of 35) were past smokers, whereas only 2 were never
smokers and 4 were current smokers. In patients with oral
cavity SCC, there was a similar lack of never smokers (3
of 45). Most patients had a smoking history (36 of 45)
but were not current smokers (6 of 45).
For patients with oral cavity SCC, several clinical cova-
riates were found to be associated with survival. On
bivariate analysis, the presence of perineural invasion in
the primary tumor (10 of 49 patients), nodal disease (27
of 49 patients), and extracapsular spread (found in 12 of
27 patients with nodal disease) were all associated with
poorer DSS (p ¼ .001, .047, and .004, respectively) and
OS (p ¼ .001, .005, and .005, respectively). No statisti-
cally significant difference was seen between those who
were positive versus those who were negative for EGFR
expression. However, patients with a score of 4 had a
trend toward both earlier disease-related events and
poorer 5-year DSS (Figure 6). After multivariable regres-
sion with perineural invasion, nodal disease, extracapsular
spread, and the biomarkers, the clinical covariates
remained statistically significant predictors of survival.
DISCUSSION
The purpose of this study was to characterize the
expression of 2 biomarkers, p16 and EGFR, in 2 separate
cohorts of surgically treated patients: the first, patients
with oropharyngeal SCC, and the second, patients with
oral cavity SCC. For patients with oropharyngeal SCC,
the results of this study demonstrate a distinct survival
advantage for those with high levels of p16 expression
and a survival disadvantage for those with high levels of
EGFR expression. As combined markers, p16 and EGFR
identified, with more accuracy, those patients with the
best and worst survival. Several studies in the literature
have demonstrated the importance of both p16 and EGFR
in predicting survival of patients with oropharyngeal
SCC; however, most are based on treatment with primary
radiotherapy and cisplatin-based chemotherapy.2,3,6–13
This study is unique in that it evaluates the predictive
power of these 2 biomarkers in 2 surgically treated
cohorts of patients with oropharyngeal SCC and shows
FIGURE 3. Survival of patients with oropharyngeal squamous cell carcinoma (SCC) according to epidermal growth factor receptor (EGFR) intensity.
(A) Those with none or low EGFR expression have significantly improved disease-specific survival (DSS). (B) Those with none or low EGFR
expression have significantly improved overall survival (OS). [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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that p16 and EGFR are predictive in surgically treated
patients. Furthermore, the patients with oropharyngeal
SCC included in this study were treated at a time when
surgery was the standard treatment for oropharyngeal
SCC at the University of Michigan.
The p16 expression assessed through immunohisto-
chemistry has now been accepted as a reliable biomarker
for the HPV E7 oncoprotein,12 thus acting as a surrogate
marker for high-risk HPV infection in oropharyngeal
SCC.1,2,11,14,15 A previous study at the University of
Michigan has demonstrated a very strong association
between p16 and HPV copy number (p < .001).2 Further,
the importance of p16 expression may extend beyond that
of being a surrogate marker of HPV infection. Lassen
et al11 argue that p16 positivity may identify HPV infec-
tions in oropharyngeal SCC that are transcriptionally
active and thus may predict patient outcome more accu-
rately than HPV detection.
A few studies have explored the role of HPV in surgi-
cally treated patients with oropharyngeal SCC.16 Licitra
et al17 performed a retrospective review of 90 consecutive
patients with oropharyngeal SCC, all treated with surgery
þ/ radiotherapy. Patients were evaluated for HPV DNA
type 16 and 18, in association with a second biomarker,
TP53. Multivariable regression analysis demonstrated that
those tumors that were both HPV positive and contained
wild-type TP53 had significantly improved survival.
Ukpo et al18 performed a retrospective review of 102
patients with oropharyngeal SCC, treated with surgery
þ/ radiotherapy. This study did not demonstrate any
association between HPV status and survival. Conversely,
Rich et al15 performed a retrospective analysis of patients
treated with transoral laser microsurgery 6 adjuvant ther-
apy. Increased expression of p16, assessed in tumors
from 73 patients, was associated with improved survival.
Interestingly, however, patients with positive HPV DNA
(determined by in situ hybridization techniques) did not
have significantly improved survival. Similar to our
study, the majority of patients in this study (93%)
received adjuvant radiotherapy. In our study, those
patients with oropharyngeal SCC who had high levels of
p16 expression had over 50% improved DSS in compari-
son with those with low levels of p16 expression at 5
years of follow-up. Although the biologic basis for the
survival advantage conferred by p16 upregulation is
unknown, a plausible explanation that prevails in the lit-
erature is that tumors expressing p16 are less hypoxic
and, therefore, respond with less accelerated repopulation
when irradiated, thus making them more susceptible to
FIGURE 4. Disease-specific survival (DSS) of patients with
oropharyngeal squamous cell carcinoma (SCC) according to
combined epidermal growth factor receptor (EGFR) intensity and p16
proportion. Those with low EGFR/high p16 have the best DSS,
whereas those with high EGFR/low p16 have the worst DSS. [Color
figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
FIGURE 5. Correlation of mean epidermal growth factor receptor
(EGFR) intensity with smoking status in patients with oropharyngeal
squamous cell carcinoma (SCC). Higher levels of EGFR expression
were associated with either past or current smoking status (r ¼
0.385; p ¼ .02) Dot, mean; box, 25th to 75th percentile; horizontal
bar, median; corr, Spearman correlation coefficient. [Color figure can
be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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radiation.11 The prevalence of p16 positivity in a large se-
ries evaluating patients with oropharyngeal SCC treated
with conventional chemoradiation ranges from 19% to
95%.3,7,9–11,14–16,18,19 Although this range is quite large,
studies that evaluate the prevalence more recently tend to
have a higher rate, suggesting an increase in the preva-
lence over time. The prevalence in our study (57%) is
consistent with the studies that have assembled patient
cohorts from a similar time period.
The prevalence of HPV in oral cavity SCC is not well
established, but a few studies quote a range from 3% to
12%.9,20 Our study demonstrated a p16 prevalence of
13%, in keeping with studies in the literature. P16 is
much less likely to be a surrogate marker for HPV status
in the oral cavity and, due to the low prevalence of p16
in our oral cavity SCC cohort, a survival analysis stratify-
ing patients by p16 status was not feasible.
The role of EGFR expression in predicting the outcome
for surgically treated patients with oropharyngeal SCC
has yet to be elucidated. Preuss et al4 conducted a retro-
spective case series of patients with oropharyngeal SCC
treated with surgery 6 radiotherapy and found no relation
between EGFR expression and survival. Many studies,
however, have demonstrated the relationship between
EGFR expression and poorer survival in patients treated
with primary chemoradiotherapy.3,5,6,8,13,21 Further, the
majority of patients in these studies demonstrate locore-
gional treatment failure, suggesting that tumors with high
EGFR intensity may be radioresistant. In this surgical
cohort, patients with high levels of EGFR expression also
experienced poorer survival but the pattern of recurrence
was different. The majority of patients treated surgically
failed distantly, suggesting that surgery may result in bet-
ter local/regional control but still requires an additional
modality to address distant disease.
Most studies evaluating the role of EGFR expression in
oral cavity SCC combine oral cavity SCC with other sub-
sites of the head and neck.6,8,13,21 One study that looked
solely at oral cavity SCC found no association between
EGFR expression and survival.22 Our study suggests that
patients with the highest score of EGFR intensity were
associated with worsened survival and shorter time to re-
currence when compared with those with lower EGFR in-
tensity scores. This is consistent with our findings in the
oropharyngeal SCC cohort. A study with a larger sample
size may be able to demonstrate a statistically significant
difference in survival in the oral cavity SCC cohort. Fur-
ther, using a higher cut-point for the score that establishes
EGFR positivity may also strengthen the ability to detect
a difference with respect to survival.
Consistent with a small number of studies in the litera-
ture, EGFR expression was associated with smoking sta-
tus in patients with oropharyngeal SCC.2,23,24 However,
smoking status was not an independent risk factor for
worsened survival in this study. The analysis was ham-
pered by a low frequency of patients with no smoking
history. This study also suggested that both ECS and peri-
vascular invasion, when considered alone, were negative
prognosticators for those with oropharyngeal SCC. One of
the mechanisms in which EGFR expression translates into
advanced local/regional disease is through angiolymphatic
invasion.25 In this study, the addition of EGFR status to
the survival model showed that EGFR expression was
more predictive of survival than extracapsular extension
and perivascular invasion, perhaps suggesting that EGFR
may represent a range of invasive behaviors that encom-
pass nodal metastasis, ECS, and perivascular invasion.
This study found that high p16/low EGFR expression
was associated with improved survival in an oropharyn-
geal SCC surgical cohort, whereas these markers were
not useful for prediction in patients with oral cavity SCC.
The use of a combination of p16 and EGFR expression to
predict survival in oropharyngeal SCC has only been
reported in patients treated with primary chemoradiother-
apy.2,3 Based on the results of this study, we recommend
that the patient with oropharyngeal SCC should have the
primary tumor stained for both EGFR and p16 regardless
of treatment modality.
CONCLUSION
This study suggests that in a surgically treated cohort
of patients with oropharyngeal SCC, increased p16
expression predicts improved survival whereas increased
EGFR expression predicts poorer survival. Used in com-
bination, the 2 biomarkers may identify those who are
likely to do well with treatment versus those who will do
poorly. In addition, the prevalence of p16 differs signifi-
cantly between the oral cavity and oropharynx subsites,
whereas the prevalence of EGFR is similar between the 2
FIGURE 6. Survival of patients with oral cavity squamous cell
carcinoma (SCC) according to epidermal growth factor receptor
(EGFR) intensity. Those with the highest expression of EGFR have a
trend toward poorer survival compared with those with none, low, or
moderate staining. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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sites. For oral cavity SCC, clinical nodal status, ECS, and
perineural invasion remain more important markers of
prognosis than p16 or EGFR.
Acknowledgements
The authors thank Tamara Miller, RN, BSN, for assis-
tance with prospectively following the patients in this
cohort and Christopher Postma, BBA, for assistance with
the article preparation.
REFERENCES
1. Chung CH, Gillison ML. Human papillomavirus in head and neck cancer:
its role in pathogenesis and clinical implications. Clin Cancer Res 2009;
15:6758–6762.
2. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV titer, Bcl-xL and
p53, sex, and smoking as indicators of response to therapy and survival in
oropharyngeal cancer. J Clin Oncol 2008;26:3128–3137.
3. Reimers N, Kasper HU, Weissenborn SJ, et al. Combined analysis of
HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyn-
geal cancer. Int J Cancer 2007;120:1731–1738.
4. Preuss SF, Weinell A, Molitor M, et al. Survivin and epidermal growth
factor receptor expression in surgically treated oropharyngeal squamous
cell carcinoma. Head Neck 2008;30:1318–1324.
5. Numico G, Russi EG, Colantonio I, et al. EGFR status and prognosis of
patients with locally advanced head and neck cancer treated with chemora-
diotherapy. Anticancer Res 2010;30:671–676.
6. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor re-
ceptor expression on survival and pattern of relapse in patients with
advanced head and neck carcinoma. Cancer Res 2002;62:7350–7356.
7. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for
organ preservation in advanced oropharynx cancer: response and survival
positively associated with HPV16 copy number. J Clin Oncol 2008;26:
3138–3146.
8. Kong CS, Narasimhan B, Cao H, et al. The relationship between human
papillomavirus status and other molecular prognostic markers in head and
neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2009;74:
553–561.
9. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal associa-
tion between human papillomavirus and a subset of head and neck can-
cers. J Natl Cancer Inst 2000;92:709–720.
10. Ringstr€om E, Peters E, Hasegawa M, Posner M, Liu M, Kelsey KT.
Human papillomavirus type 16 and squamous cell carcinoma of the head
and neck. Clin Cancer Res 2002;8:3187–3192.
11. Lassen P, Eriksen JG, Hamilton–Dutoit S, Tramm T, Alsner J, Overgaard
J. Effect of HPV-associated p16INK4A expression on response to radio-
therapy and survival in squamous cell carcinoma of the head and neck.
J Clin Oncol 2009;27:1992–1998.
12. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and
survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:
24–35.
13. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor
receptor gene copy number is associated with poor prognosis in head and
neck squamous cell carcinomas. J Clin Oncol 2006;24:4170–4176.
14. Nichols AC, Faquin WC, Westra WH, et al. HPV-16 infection predicts
treatment outcome in oropharyngeal squamous cell carcinoma. Otolaryn-
gol Head Neck Surg 2009;140:228–234.
15. Rich JT, Milov S, Lewis JS Jr, Thorstad WL, Adkins DR, Haughey BH.
Transoral laser microsurgery (TLM) þ/ adjuvant therapy for advanced
stage oropharyngeal cancer: outcomes and prognostic factors. Laryngo-
scope 2009;119:1709–1719.
16. Haughey BH, Hinni ML, Salassa JR, et al. Transoral laser microsurgery as
primary treatment for advanced-stage oropharyngeal cancer: a United
States multicenter study. Head Neck 2011;33:1683–1694.
17. Licitra L, Perrone F, Bossi P, et al. High-risk human papillomavirus
affects prognosis in patients with surgically treated oropharyngeal squa-
mous cell carcinoma. J Clin Oncol 2006;24:5630–5636.
18. Ukpo OC, Pritchett CV, Lewis JE, Weaver AL, Smith DI, Moore EJ.
Human papillomavirus-associated oropharyngeal squamous cell carcino-
mas: primary tumor burden and survival in surgical patients. Ann Otol
Rhinol Laryngol 2009;118:368–373.
19. Ritchie JM, Smith EM, Summersgill KF, et al. Human papillomavirus
infection as a prognostic factor in carcinomas of the oral cavity and oro-
pharynx. Int J Cancer 2003;104:336–344.
20. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and
oral cancer: the International Agency for Research on Cancer multicenter
study. J Natl Cancer Inst 2003;95:1772–1783.
21. Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal
growth factor receptor and survival in upper aerodigestive tract cancer.
J Clin Oncol 1993;11:1873–1878.
22. Smid EJ, Stoter TR, Bloemena E, et al. The importance of immunohisto-
chemical expression of EGFr in squamous cell carcinoma of the oral cav-
ity treated with surgery and postoperative radiotherapy. Int J Radiat Oncol
Biol Phys 2006;65:1323–1329.
23. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in
head and neck cancer. J Clin Oncol 2006;24:2666–2672.
24. Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papilloma-
virus-positive advanced oropharynx cancer patients related to increased
risk of distant metastases and tumor recurrence. Clin Cancer Res 2010;16:
1226–1235.
25. Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor recep-
tor expression in pretreatment biopsies from head and neck squamous cell
carcinoma as a predictive factor for a benefit from accelerated radiation
therapy in a randomized controlled trial. J Clin Oncol 2005;23:
5560–5567.
CHANDARANA ET AL.
1090 HEAD &NECK—DOI 10.1002/HED AUGUST 2013
